Suzuki K, et al. - Among patients with relapsed or refractory multiple myeloma (RRMM) (n = 59) managed with lenalidomide, researchers assessed the clinical significance of raised eosinophil levels (defined as a rise in the eosinophil count of ≥ 250/µL from the eosinophil count on day 1 during the first cycle). The percentage of patients exhibiting high eosinophil levels was 22.0%. In the elevated eosinophil group and nonelevated eosinophil group, the overall response ratio was found to be 84.6% and 63.0%, respectively. The elevated eosinophil group vs the nonelevated group had significantly longer median time to next treatment (TTNT). Overall, the presence of high eosinophil levels was a frequent finding in patients with RRMM treated with lenalidomide, and elevated eosinophil levels might be predictive of a longer TTNT in these patients.